Current understanding of reovirus oncolysis mechanisms
نویسندگان
چکیده
منابع مشابه
Activation of p53 by Chemotherapeutic Agents Enhances Reovirus Oncolysis
Mammalian reovirus is a benign virus that possesses the natural ability to preferentially infect and kill cancer cells (reovirus oncolysis). Reovirus exploits aberrant Ras signalling in many human cancers to promote its own replication and spread. In vitro and in vivo studies using reovirus either singly or in combination with anti-cancer drugs have shown very encouraging results. Presently, a ...
متن کاملReovirus Oncolysis - Role of cyclin-dependent kinase inhibitor 1
New therapeutic interventions are essential for improved cancer management. Over the past decade, reovirus, a naturally-occurring oncolytic double-stranded RNA virus harboring an intrinsic preference to destroy mutant KRAS driven tumors, has shown novel promissory potential. The fact that more than 30-40% of human tumors harbor KRAS mutations had previously guided us to investigate the efficacy...
متن کاملPotential for Improving Potency and Specificity of Reovirus Oncolysis with Next-Generation Reovirus Variants
Viruses that specifically replicate in tumor over normal cells offer promising cancer therapies. Oncolytic viruses (OV) not only kill the tumor cells directly; they also promote anti-tumor immunotherapeutic responses. Other major advantages of OVs are that they dose-escalate in tumors and can be genetically engineered to enhance potency and specificity. Unmodified wild type reovirus is a propit...
متن کاملMechanisms of Oncolysis by Paramyxovirus Sendai
Some viral strains of the Paramyxoviridae family may be used as anti-tumor agents. Oncolytic paramyxoviruses include attenuated strains of the measles virus, Newcastle disease virus, and Sendai virus. These viral strains, and the Sendai virus in particular, can preferentially induce the death of malignant, rather than normal, cells. The death of cancer cells results from both direct killing by ...
متن کاملActivated Ras Signaling Pathways and Reovirus Oncolysis: An Update on the Mechanism of Preferential Reovirus Replication in Cancer Cells
The development of wild-type, unmodified Type 3 Dearing strain reovirus as an anticancer agent has currently expanded to 32 clinical trials (both completed and ongoing) involving reovirus in the treatment of cancer. It has been more than 30 years since the potential of reovirus as an anticancer agent was first identified in studies that demonstrated the preferential replication of reovirus in t...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Oncolytic Virotherapy
سال: 2018
ISSN: 2253-1572
DOI: 10.2147/ov.s143808